Data on Oral Contraceptives Compliance in Non Stop Regimen
Completed
- Conditions
- Contraception
- Interventions
- Drug: Qlaira or Yaz (BSP products defined as Combined Oral Contraceptive) and Cerazette or Azalia (competitor's products defined as Progestogen Only Pill)
- Registration Number
- NCT01185678
- Lead Sponsor
- Bayer
- Brief Summary
Adherence to the dosing scheme is the principal element of COC efficiency. On the other hand noncompliance seemed to be an inseparable element of any oral treatment. The aim of the study is to evaluate in everyday practice the relation between dosage errors and indicated factors, potentially influencing the compliance with the dosing scheme.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 8416
Inclusion Criteria
- Patients at the age of 18-50 requiring contraception, treated with oral contraceptives designed for the scheme 28 pills for 28 days. The decisions would be made at the discretion of the attending physician.
Read More
Exclusion Criteria
- Patients were not valid for analysis if the initial visit was before start of study in the country (retrospective documentation), or if they did not take oral contraceptives designed for the scheme 28 pills for 28 days.
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Group1 Qlaira or Yaz (BSP products defined as Combined Oral Contraceptive) and Cerazette or Azalia (competitor's products defined as Progestogen Only Pill) -
- Primary Outcome Measures
Name Time Method The percentage of users showing noncompliant behaviors 3 consecutive cycles (28-days per cycle)
- Secondary Outcome Measures
Name Time Method The characteristics of noncompliant behavior. 3 consecutive cycles (28-days per cycle) The relation between noncompliant behavior and selected factors. 3 consecutive cycles (28-days per cycle)